Deal facts
- Buyer
- HSI
- Target
- Sonnet BioTherapeutics Holdings, Inc.
- Deal value
- Not disclosed
- Announced
- 3 December 2025
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- shares
Sources
HSI has agreed to acquire Sonnet BioTherapeutics Holdings, Inc. in a going private transaction valued at an undisclosed amount. The deal consideration consists of shares, with the buyer and target both based in the United States within the Healthcare sector. Although the announcement was made on 3 December 2025, the transaction is recorded as completed on 2 December 2025. No specific financial figures or currency details were reported for this acquisition.
The transaction marks the removal of Sonnet BioTherapeutics Holdings from public markets. HSI will assume full ownership of the company following the exchange of shares for the target's equity. This move concludes the public listing status for the biotechnology firm. The transaction is now complete and subject to no further regulatory conditions.
More M&A Tools
Explore the Toolkit
Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.
Access nowDeal timeline
1 update- CompletedClosed
HSI completes acquisition of Sonnet BioTherapeutics Holdings, Inc.
Item 2.01 for additional information regarding completion of the Business Combination. Item 2.01 Completion of Acquisition or Disposition of Assets. The disclosure set forth in the “Explanatory Note” is incorporated by reference into this Item 2.01. On the Closing Date, HSI, Sonnet and Rorschach completed the Business Combination and the other transactions contemplated by the BCA, including the Me
Source
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
CCP PAW 2 LIMITED to acquire ANIMALCARE GROUP PLC
CCP PAW 2 Limited has agreed to acquire Animalcare Group Plc in a going private transaction. The deal was announced and completed on 30 July 2026. Both the buyer and the…
- Buyer
- CCP PAW 2 LIMITED
- Target
- ANIMALCARE GROUP PLC
- Deal value
- Not disclosed
- Deal type
- going private
argenx BV to acquire Forte Biosciences, Inc.
argenx BV has agreed to acquire Forte Biosciences, Inc. in a going private transaction valued at USD 2.2 billion. The Belgian listed biotechnology company is purchasing…
- Buyer
- argenx BV
- Target
- Forte Biosciences, Inc.
- Deal value
- USD 2,200,000,000
- Deal type
- going private
Vertex Pharmaceuticals Incorporated to acquire Crinetics Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated has agreed to acquire Crinetics Pharmaceuticals, Inc. in a going private transaction valued at $10 billion. The deal, announced on 6…
- Buyer
- Vertex Pharmaceuticals Incorporated
- Target
- Crinetics Pharmaceuticals, Inc.
- Deal value
- USD 10,000,000,000
- Deal type
- going private
Trafalgar Asset Management, LLC to acquire The Greater Cannabis Company, Inc.
Trafalgar Asset Management, LLC has agreed to acquire The Greater Cannabis Company, Inc. in a going private transaction. The deal was announced on 6 July 2026, following…
- Buyer
- Trafalgar Asset Management, LLC
- Target
- The Greater Cannabis Company, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Hanmi Pharmaceuticals Co. Ltd. to acquire Aptose Biosciences Inc.
Hanmi Pharmaceuticals Co. Ltd. has agreed to acquire Aptose Biosciences Inc. in a going private transaction valued at USD 3,466,470. The consideration for this deal cons…
- Buyer
- Hanmi Pharmaceuticals Co. Ltd.
- Target
- Aptose Biosciences Inc.
- Deal value
- USD 3,466,470
- Deal type
- going private
Buyer history
HSI
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive